Published in Curr Opin Gastroenterol on July 01, 2003
Ulcerative colitis. N Engl J Med (2011) 6.14
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology (2003) 2.53
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology (2006) 2.35
Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 2.22
Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol (2006) 1.79
Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol (2007) 1.64
Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev (2004) 1.61
The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol (2005) 1.55
Intestinal fibrosis in IBD--a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol (2009) 1.51
Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol (2004) 1.51
Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.49
Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol (2011) 1.45
Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology (2003) 1.42
Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities. Gastroenterology (2006) 1.41
Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis (2007) 1.30
Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am J Pathol (2009) 1.27
Interleukin 1beta-induced production of H2O2 contributes to reduced sigmoid colonic circular smooth muscle contractility in ulcerative colitis. J Pharmacol Exp Ther (2004) 1.27
Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut (2006) 1.26
Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol (2006) 1.23
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest (2014) 1.20
CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology (2004) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol (2004) 1.17
Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am J Physiol Gastrointest Liver Physiol (2004) 1.17
Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis (2010) 1.12
Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis (2005) 1.10
Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol (2005) 1.04
Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol (2004) 1.04
Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol (2011) 1.03
An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol (2005) 1.03
Hyaluronan (HA) deposition precedes and promotes leukocyte recruitment in intestinal inflammation. Clin Transl Sci (2008) 1.02
Closing fistulas in Crohn's disease--should the accent be on maintenance or safety? N Engl J Med (2004) 1.02
Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis (2002) 0.97
Corticotropin-releasing hormone family of peptides regulates intestinal angiogenesis. Gastroenterology (2010) 0.97
Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives. J Crohns Colitis (2008) 0.96
Redox equilibrium in mucosal T cells tunes the intestinal TCR signaling threshold. J Immunol (2005) 0.95
Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. Curr Opin Gastroenterol (2013) 0.95
Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol (2012) 0.93
p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling. J Clin Invest (2002) 0.93
Acid-induced release of platelet-activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle. J Pharmacol Exp Ther (2006) 0.93
HCl-induced inflammatory mediators in cat esophageal mucosa and inflammatory mediators in esophageal circular muscle in an in vitro model of esophagitis. Am J Physiol Gastrointest Liver Physiol (2006) 0.92
Platelet-activating factor and prostaglandin E2 impair esophageal ACh release in experimental esophagitis. Am J Physiol Gastrointest Liver Physiol (2005) 0.92
HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2012) 0.92
Critical role of caspases in the regulation of apoptosis and proliferation of mucosal T cells. Gastroenterology (2002) 0.92
Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol (2008) 0.91
Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis (2014) 0.91
Hydrogen peroxide reduces lower esophageal sphincter tone in human esophagitis. Gastroenterology (2005) 0.90
Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology (2006) 0.90
Pathogenesis of postoperative recurrence in Crohn's disease. Gut (2010) 0.90
In vitro model of acute esophagitis in the cat. Am J Physiol Gastrointest Liver Physiol (2005) 0.89
Hydrogen peroxide contributes to motor dysfunction in ulcerative colitis. Am J Physiol Gastrointest Liver Physiol (2003) 0.89
HCl-induced inflammatory mediators in esophageal mucosa increase migration and production of H2O2 by peripheral blood leukocytes. Am J Physiol Gastrointest Liver Physiol (2010) 0.88
Production of IL-1beta, hydrogen peroxide, and nitric oxide by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis. Am J Physiol Cell Physiol (2005) 0.88
Inflammatory bowel disease. Best Pract Res Clin Gastroenterol (2002) 0.87
Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase. PLoS One (2011) 0.86
Intestinal fibroblast-derived IL-10 increases survival of mucosal T cells by inhibiting growth factor deprivation- and Fas-mediated apoptosis. J Immunol (2005) 0.85
Mechanisms of tissue remodeling in inflammatory bowel disease. Dig Dis (2013) 0.85
Inflammatory bowel disease-associated gene expression in intestinal epithelial cells by differential cDNA screening and mRNA display. Inflamm Bowel Dis (2003) 0.85
Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. Curr Drug Targets (2008) 0.84
Progress in basic inflammatory bowel disease research. Semin Pediatr Surg (2007) 0.82
Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease. Gastroenterology (2012) 0.81
Gene-gene interactions in inflammatory bowel disease: biological and clinical implications. Am J Gastroenterol (2009) 0.81
Dual function of the extracellular matrix: stimulatory for cell cycle progression of naive T cells and antiapoptotic for tissue-derived memory T cells. J Immunol (2004) 0.80
News from the "5th International Meeting on Inflammatory Bowel Diseases" CAPRI 2010. J Crohns Colitis (2010) 0.80
Tailoring Treatment to the Individual Patient - Will Inflammatory Bowel Disease Medicine Be Personalized? Dig Dis (2015) 0.79
The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8. Am J Physiol Gastrointest Liver Physiol (2009) 0.79
Gene-gene and gene-environment interactions in ulcerative colitis. Hum Genet (2013) 0.79
Impact of abdominal visceral adipose tissue on disease outcome in pediatric Crohn's disease. Inflamm Bowel Dis (2014) 0.79
Inflammatory bowel disease: evolutionary concepts in biology, epidemiology, mechanisms and therapy. Curr Opin Gastroenterol (2013) 0.79
A novel approach to detect cumulative genetic effects and genetic interactions in Crohn's disease. Inflamm Bowel Dis (2013) 0.78
IBD: advances in pathogenesis, complications, diagnosis, and therapy. Curr Opin Gastroenterol (2012) 0.78
Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology (2012) 0.78
Significance of glucocorticoid receptor expression in colonic mucosal cells of patients with ulcerative colitis. World J Gastroenterol (2005) 0.78
Paradoxical decrease of mitochondrial DNA deletions in epithelial cells of active ulcerative colitis patients. Am J Physiol Gastrointest Liver Physiol (2004) 0.77
Early and late inflammatory bowel disease: why and how are they different? Curr Opin Gastroenterol (2011) 0.77
Probiotics in inflammatory bowel disease: yet another mechanism of action? Gastroenterology (2006) 0.77
Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006. Inflamm Bowel Dis (2007) 0.76
Inflammatory bowel disease: new insights into mechanisms of inflammation and increasingly customized approaches to diagnosis and therapy. Curr Opin Gastroenterol (2004) 0.76
Targeting the innate immune system in pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol (2011) 0.76
Atherosclerosis and inflammatory bowel disease: sharing a common pathogenic pathway? Circulation (2003) 0.76
Eosinophilic esophagitis: new insights into an emerging disease. Gastroenterology (2006) 0.75
Inflammatory bowel disease: genetics and much more. Curr Opin Gastroenterol (2002) 0.75
Current perspectives in inflammatory bowel disease: stress response and autophagy, host-microbe mutualism, immune duality and plasticity, and early versus late disease. Curr Opin Gastroenterol (2010) 0.75
Endothelial Cell-Immune Cell Interaction in IBD. Dig Dis (2016) 0.75
Non-stop progress in inflammatory bowel disease: new players, new understanding, new therapies. Curr Opin Gastroenterol (2006) 0.75
First international summit on fibrosis in intestinal inflammation: mechanisms and biological therapies. Fibrogenesis Tissue Repair (2010) 0.75